Current challenges in clinical development of “targeted therapies”: the case of acute myeloid leukemia
E Estey, RL Levine, B Löwenberg - Blood, The Journal of the …, 2015 - ashpublications.org
A fundamental difficulty in testing “targeted therapies” in acute myeloid leukemia (AML) is
the limitations of preclinical models in capturing inter-and intrapatient genomic …
the limitations of preclinical models in capturing inter-and intrapatient genomic …
[HTML][HTML] Current challenges in clinical development of “targeted therapies”: the case of acute myeloid leukemia
E Estey, RL Levine, B Löwenberg - Blood, 2015 - Elsevier
A fundamental difficulty in testing “targeted therapies” in acute myeloid leukemia (AML) is
the limitations of preclinical models in capturing inter-and intrapatient genomic …
the limitations of preclinical models in capturing inter-and intrapatient genomic …
Current challenges in clinical development of" targeted therapies": the case of acute myeloid leukemia
E Estey, RL Levine, B Löwenberg - Blood, 2015 - pubmed.ncbi.nlm.nih.gov
A fundamental difficulty in testing" targeted therapies" in acute myeloid leukemia (AML) is
the limitations of preclinical models in capturing inter-and intrapatient genomic …
the limitations of preclinical models in capturing inter-and intrapatient genomic …
Current challenges in clinical development of “targeted therapies”: the case of acute myeloid leukemia
E Estey, RL Levine, B Löwenberg - Blood, 2015 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> A fundamental difficulty in testing “targeted
therapies” in acute myeloid leukemia (AML) is the limitations of preclinical models in …
therapies” in acute myeloid leukemia (AML) is the limitations of preclinical models in …
Current challenges in clinical development of" targeted therapies": The case of acute myeloid leukemia
E Estey, R Levine, B Löwenberg - Blood, 2015 - repub.eur.nl
A fundamental difficulty in testing" targeted therapies" in acute myeloid leukemia (AML) is
the limitations of preclinical models in capturing inter-and intrapatient genomic …
the limitations of preclinical models in capturing inter-and intrapatient genomic …
Current challenges in clinical development of" targeted therapies": the case of acute myeloid leukemia.
E Estey, RL Levine, B Löwenberg - Blood, 2015 - europepmc.org
A fundamental difficulty in testing" targeted therapies" in acute myeloid leukemia (AML) is
the limitations of preclinical models in capturing inter-and intrapatient genomic …
the limitations of preclinical models in capturing inter-and intrapatient genomic …